StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Other Vaccines & Immune Therapies by Quarter

Other Vaccines & Immune Therapies — Europe product sales ($M) ($M)

AstraZeneca Other Vaccines & Immune Therapies: $1M in Q2 2026.

Latest, Q2 2026
1
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
10
Documents cited below

Where the Q2 2026 figure comes from

“|| Other ID | | 34 | | ( 31 ) | | ( 34 ) | | ( 1 ) | | 73 | | 30 | | ( 20 ) | | ( 26 ) | | 1 | | 78 | | 69 | | 4 | | ( 68 ) | | ( 66 )”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Vaccines & Immune Therapies — Europe product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261–Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202615+1,400.0%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20250-100.0%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 20250–Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 20250–Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 20251-83.3%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024-4–Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 20240–Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 20240–Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 20246–Form 6-K FY2024Q1 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Other Vaccines & Immune Therapies ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-other-vi-eu

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.